Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments

BACKGROUND: An aerosol foam formulation of fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0.5 mg/g (as dipropionate; BD) has been developed for psoriasis vulgaris treatment. OBJECTIVE: To compare Cal/BD aerosol foam pharmacodynamic activity with Cal/BD ointment and with other topical...

Descripción completa

Detalles Bibliográficos
Autores principales: Queille‐Roussel, C., Bang, B., Clonier, F., Lacour, J.‐P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108427/
https://www.ncbi.nlm.nih.gov/pubmed/27306589
http://dx.doi.org/10.1111/jdv.13714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108427/
https://www.ncbi.nlm.nih.gov/pubmed/27306589
http://dx.doi.org/10.1111/jdv.13714

Ejemplares similares